6. PUBLICATIONS (last updated 4-06)

6.1 Published Case Reports and Letters
1. Robinson BWS. Henoch-Schonlein purpura due to food sensitivity. Br Med J 1977; 1: 510-511.
2. Robinson BWS, Corless D. Spurious polycythaemia resolving during observation. Br Med J 1978; 2: 280.
3. Robinson BWS. Medical screening of old people. Lancet 1978; 2: 532.
4. Robinson BWS. Death from asthma. Med J Aust 1980; 1: 144.
5. Robinson BWS. Joske RA. Familial Mediterranean fever in Australia. Med J Aust 1980; 1: 494.
6. Robinson BWS. Bone-scanning in hypertrophic osteoarthropathy. Thorax 1980; 35: 960.
8. Robinson BWS. Lewis RR. Myocardial metastasis from carcinoma of the pancreas presenting as acute myocardial infarction. Proc Roy Soc Med 1982; 75: 560-562.
61. Robinson BWS. Doctor in pain - learning as a patient. Med J Aust 1992;156:669.
Lee YC, Chew GT, Robinson BWS. Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis. Aust NZ J Med 1999;29(6):843-4.
6.2 Papers
7. Robinson BWS, Musk AW. Benign asbestos pleural effusion - diagnosis and course. Thorax 1981; 36: 896-900.
9. Robinson BWS. Nitrofurantoin-induced interstitial pulmonary fibrosis. Med J Aust 1983; 1: 72-76.
10. Robinson BWS, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest 1984; 74: 942-50.
11. Venet A, Hance AJ, Saltini C, Robinson BWS, Crystal RG. Enhanced alveolar macrophage-mediated antigen induced T lymphocyte proliferation in sarcoidosis. J Clin Invest 1985; 75: 293-301.
12. Robinson BWS, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-1495.
13. Robinson BWS, Rose AH, Hey A, Whitaker D, Musk AW. Alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite- and chysotile-exposed individuals. Chest 1986; 90: 396-402.
14. Holt P, Robinson BWS, Reid M, Kees U, Warton A, Dawson V, Rose AH, Schon-Hegrad M, Papadimitrou J. Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic digestion procedure. Clin Exp Immunol 1986; 66: 188-200.
15. Robinson BWS, Morstyn G. Interleukin-2-activated Natural Killer cells are active against lung cancer cells. Chest 1987; 91: 31-32.
16. Robinson BWS, Rose A, Thompson PJ, Hey A. Comparison of bronchoalveolar lavage helper/suppressor T-cell ratios in sarcoidosis versus other interstitial lung diseases. Aust NZ J Med 1987; 17: 9-15.
17. Robinson BWS. Evaluation of pulmonary anti-cancer and inflammatory processes in humans. MD Thesis. 1987. Uni of W Australia.
18. Robinson BWS, Morstyn G. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells. Cell Immunol 1987; 106: 215-222.
19. Robinson BWS, James A, Rose A, Sterret G, Musk AW. Bronchoalveolar lavage sampling of airway and alveolar cells. Br J Dis Chest 1988; 82: 45-55.
20. Robinson BWS, Rose AH, Hayes A, Musk AW. Increased pulmonary gamma interferon production in asbestosis. Am Rev Respir Dis 1988; 138: 278-283.
21. Robinson BWS. Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung diseases. Thorax 1988; 43: 508-515.
22. Holt PG, Kees UR, Schon-Hegrad MA, Rose A, Ford J, Bilyk N, Bowman R, Robinson BWS. Limiting dilution analysis of T cells extracted from solid human lung tissue: comparison of precursor frequencies for proliferative responses and lymphokine production between lung and blood T cells from individual donors. Immunology 1988; 64: 649-654.
23. Hayes A, Rose AH, Musk AW, Robinson BWS. Neutrophil chemotactic factor release and neutrophil alveolitis in asbestos-exposed individuals. Chest 1988; 94: 521-525.
24. Warton A, Papadimitriou JM, Venaille TJ, Mendis SHW, Robinson BWS. Human amnion membrane as a model for studying the host-parasite relationship in trichomoniasis. Int J Parasitol 1988; 18: 1003-1005.
25. Robinson BWS, Kees UR, Holt PG. Lung interstitial natural killer cells in patients with lung cancer: presence, activity and response to interleukin-2. Lung Cancer 1989; 5: 41-48.
26. Hayes A, Mullan B, Lovegrove FT, Robinson BWS, Musk AW. Gallium lung scanning and bronchoalveolar lavage in crocidolite-exposed workers. Chest 1989; 96: 22-26.
27. Manning L, Bowman RV, Darby SB, Robinson BWS. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis, 1989; 139: 1369-1374.
28. Gibson PG, Robinson BWS, McLennan G, Bryant DH, Breit SN. The role of bronchoalveolar lavage in the assessment of diffuse lung diseases. Aust NZ J Med 1989; 19: 281-291.
29. Robinson BWS. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibres but can be restored by recombinant interleukin-2. Am Rev Respir Dis, 1989; 139: 897-901.
30. Venaille T, Mendis A, Warton A, Walker L, Papadimitriou J, Robinson BWS. Study of human epithelial cell detachment and damage: development of a model. Immunol Cell Biol 1989; 67: 359-369.
31. Mendis AHW, Venaille T, Robinson BWS. Study of human epithelial cell detachment and damage: effects of proteases and oxidants. Immunol and Cell Biol 1990; 68:95-105.
32. Hayes A, Venaille TJ, Rosse AH, Musk AW, Robinson BWS. Asbestos-induced release of a human alveolar macrophage-derived neutrophil chemotactic factor. Exp Lung Res 1990;16:121-130.
33. Robinson BWS, Rose AH. Pulmonary g interferon production in patients with fibrosing alveolitis. Thorax 1990;45:105-108.
34. Flexman J, Manning L, Robinson BWS. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: Comparison of systemic, intrapleural and inhalation routes. Clin Exp Immunol 1990; 82:151-156.
35. Robinson BWS, Venaille TJ, Mendis AHW, McAleer R. Allergens as proteases: an aspergillus fumigatus proteinase directly induces human epithelial cell detachment. J Allergy Clin Immunol 1990; 86:726-731.
36 Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW. Malignant mesothelioma: studies of immunological anti-cancer processes. In G Peters, Ed. Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, chap 5. 1989. Garland Publishing Inc, New York. 153-172.
37. Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW. Evaluation of pulmonary inflammatory processes in asbestos-exposed individuals. In G Peters, Ed. Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, 1989. chap. 9 Garland Publishing Inc, New York. 277-296.
38. Phillips MJ, Venaille TJ, Mendis AHW, Thompson PJ, Robinson BWS. Effect of nedocromil sodium on neutrophil and eosinophil-induced epithelial cell desquamation in a human in vitro epithelial model. Drugs 1989; 37: 56-62.
39. Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BWS. Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma. Clin Immunol and Immunopath 1989; 53: 68-77.
40 Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW. Malignant mesothelioma: studies of immunological anti-cancer processes. In "Asbestos Diseases Update", Chap, 4. Garland Publishing Inc, New York, 1989.
41. Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW. Pulmonary inflammation in asbestos-exposed individuals. In "Asbestos Diseases Update", Chap 1. Garland Publishing Inc, New York, 1989.
42. Whitaker DW, Manning LS, Robinson BWS, Shilkin K. The pathobiology of the mesothelium. In Henderson DW, Shilkin K, Langlois S, Whitaker D eds. Malignant Mesothelioma. 1992. Hemisphere Publishing Corp. New York. 25-68
43. Robinson BWS. After the Fellowship - basic research? Med J Aust 1990;153:692-696
44. Bowman R, Manning LS, Davis M, Robinson BWS. Capacity of tumour necrosis f factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma. Clin Immunol Immunopath 1991;58:80-91
45. Manning LS, Murch A, Garlepp MJ, Davis MR, Musk A, Robinson BWS. Establishment and characterisation of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991;47:285-290.
47. Manning L, Davis M, Robinson BWS. Asbestos fibres inhibit the in vitro activity of lymphokines-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma. Clin Exp Immunol 1991;83:85-91.
48. Robinson BWS, Bowman R, Christmas T, Musk AW, Manning LS. Immunotherapy for malignant mesothelioma: use of interleukin-2 and interferon alpha. Interferons and Cytokines 1991;18:5-7.
49. Robinson BWS, Manning LS, Christmas TI, Bowman RV, Davis MR, Musk AW. Immunotherapy of malignanat mesothelioma: Studies using IL2/LAK cells and interferon alpha 2a. In Hersey P Ed. Biological Agents in the Treatment of Cancer. New South Wales Government Printing Office, Sydney, 1990; 414-423.
50. Manning LS, Rose, AH, Bowman RV, Christmas TI, Garlepp MJ, Robinson BWS. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In Henderson DW, Shilkin K, Langlois S, Whitaker D, eds. Malignant Mesothelioma. 1992. Hemisphere Publishing Corp. New York. 278-291.
51. Robinson BWS, Sterrett G. Bronchiolitis obliterans associated with polyarteritis nodosa. Chest 1992 102:309-311
52. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp M. HLA antigen expression and malignant mesothelioma. Am J Resp Cell Mol Biol. 1991;5:213-220.
53. Bowman R, Whitaker D, Manning LS, Davis MR, Robinson BWS. Interaction between Dactinomycin and tumor necrosis factor in mesothelioma - cachexia without oncolysis. Cancer 1991;67:2495-2500.
54. Bowman R, Manning LS, Davis MR, Robinson BWS. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother Pharmacol 1991;28:420-426.
55. Robinson BWS. Organic dust disease; mediators and mechanisms. In: Rylander R and Musk AW (eds). Workshop on Health Effects of Grain and Other Organic Dusts, Committee on Organic Dusts, ICOH, 26-29.
56. Robinson BWS. Doctor in pain - learning as a patient. Med J Aust 1992 156:355-357
57. Robinson BWS, Venaille T, Blum R, Mendis AH. Eosinophils and major basic protein damage but do not detach human amniotic epithelial cells. Exp Lung Res 1992;18:583-593
58. Holt PG, Clough JB, Holt BJ, Baron-Hay MJ, Rose AH, Robinson BWS, Thomas WR. Genetic 'risk' for atopy is associated with delayed postnatal maturation of T-cell competence. Clin Exp Allergy 1992;22:1093-99.
59. Davis MR, Manning LS, Whitaker D, Robinson BWS. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992 52:881-886.
60. Garlepp MJ, Rose AH, Bowman RV, Mavaddat N, Dench J, Holt BJ, Baron-Hay M, Holt PG, Robinson BWS. A clonal analysis of lung T cells derived by bronchoalveolar lavage of healthy individuals. Immunology 1992 77:31-37
62. Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BWS. Effect of Interferon a -2a on malignant mesothelioma. J Interferon Res 1993;13:9-12.
63. Manning LS, Davis MR, Bielefeldt-Ohmann H, Marzo AL, Garlepp MJ, Whitaker D, Robinson BWS. Evaluation of immunogenicity of murine mesothelioma cells by immunization. Europ Resp Rev 1993;3(11):234-237.
64. Robinson BWS, Bowman RV, Manning LS, Musk AW, Van Hazel GA. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. Europ Resp Rev; 1993;3(11):220-222.
65. Robinson BWS. Cell reactions and inflammation. In Rylander R, Jacobs RR, eds. Handbook on Organic Dusts. 1994, CRC Press, Boca Raton Florida, 95-107.
66. Garlepp MJ, Christmas TI, Manning LS, Davis MR, Robinson BWS. Constitutive and inducible HLA antigen expression in malignant mesothelioma. Europ Resp Rev 1993 3:11:231-233.
67. Garlepp MJ, Christmas TI, Mutsaers SE, Manning LS, Davis M, Robinson BWS. Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. Europ Resp Rev 1993;3(11):192-194.
68. Garlepp MJ, Fitzpatrick D, Mutsaers S, Bielefeldt-Ohmann H, David M,
Robinson BWS. Mesothelioma: recent studies of growth regulation. In G Peters (ed): Sourcebook on Asbestos Diseases; vol 8, 1993 Garland publishing Inc, New York. 201-218.
69. Garlepp MJ, Christmas TI, Manning LS, Mutsaers S, Dench J, Leong C, Robinson BWS. The role of platelet-derived growth factor in the growth of human malignant mesothelioma. Eur Respir Rev 1993;3(11):189-191.
70. Robinson BWS, Manning LS, Bowman RV, Christmas TI, Musk AW, Davis MR, Bielefeldt-Ohmann H, Upham J, Garlepp MJ. The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 1993;3(11):195-198.
71. Upham J, Musk AW, Robinson BWS. Mesothelioma: new therapeutic approches. In G Peters (ed): Sourcebook on Asbestos Diseases; vol 8, 1993 Garland publishing Inc, New York. 191-200.
72. Mavaddat N, Robinson BWS, Rose AH, Manning LS, Garlepp MJ. An analysis of the relationship between gd T cell receptor V gene usage and non-major histocompatability complex-restricted cytotoxicity. Immunol & Cell Biol 1993 71:27-37
73. Davis M, Manning LS, Whitaker D, Garlepp MJ, Robinson BWS. A murine model of mesothelioma. Eur Respir Rev 1993;3(11):116-117.
74. Robinson BWS. Immunobiology and immunotherapy of malignant mesothelioma. In: Mesothelial Cell and Mesothelioma, J Bignon, MC Jaurand (eds). Lung Biology in Health and Disease, Volume 78. New York 1994; 253-266.
75. Upham J, Garlepp MJ, Musk AW, Robinson BWS. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995;50:887-893.
76. Robinson BWS. Development of new therapeutic strategies for mesothelioma. Lung Cancer 1993;9:413-418.
77 Upham JW, Musk AW, van Hazel G, Byrne M, Robinson BWS. Interferon alpha and doxorubicin in malignant mesothelioma. Aust NZ J Med 1993;23:683-687.
78. Robinson BWS. Immunotherapy strategies in patients with mesothelioma. Cancer Forum 1993;17:106-111.
79. Venaille TJ, Musk AW, Robinson BWS. Direct effects of selected occupational asthma-inducing agents on human epithelial cells. J Occup Health Safety 1993;9:435-446.
80. Garlepp MJ, Dench JE, Rose AH, Robinson BWS. Clonal analysis of lung and blood T cells in patients with sarcoidosis. Thorax 1994;49:577-585.
81. Upham JW, McMenamin C, Schon-Hegrad MA, Robinson BWS, Holt PG. Functional analysis of human bronchial mucosal T cells extracted with Interleukin-2. Am J Respir Crit Care Med 1994;149:1608-1613.
82. Richardson DR, Cameron K, Robinson BWS, Turner KJ. The mechanisms of IgE uptake by human alveolar macrophages and a human B-lymphoblastoid cell line (Wil-2wt). Immunology 1993;79:305-311.
83. Christmas TI, Manning LS, Mutsaers SE, Dench J, Leong C, Robinson BWS, Garlepp MJ. Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. Eur Respir Rev 1993;3(11):192-194
84. Venaille TJ, Misso NLA, Phillips MJ, Robinson BWS, Thompson PJ. Effects of different density gradient separation techniques on neutrophil function. Scand J Clin Lab Invest 1994:54;385-391.
85. Leong C, Robinson BWS, Garlepp M. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int J Cancer 1994;59:212-216.
86. Venaille TJ, Mendis AHW, Phillips MJ, Thompson PJ, Robinson BWS. Role of neutrophils in mediating human epithelial cell detachment from native basement membrane. J Allergy Clin Immunol 1995:95;597-606.
87. Robinson BWS, Davidson JA, Garlepp MJ. The immunology and immunopathology of malignant mesothelioma. Kradin RL, Robinson BWS eds. In: Immunopathology of lung disease. Butterworth Heinemann, Stoneham, MA 1996:91-513.
88. McLennan G, Walsh RL, Robinson BWS. Bronchalveolar Lavage. Kradin RL, Robinson BWS eds. In: Immunopathology of lung disease. Butterworth Heinemann, Stoneham, MA 1996:529-540.
89. Robinson BWS, Sellner L, Redwood A, leong CC, Davidson JA, Peroni DJ, Marzo AL, Garlepp MJ and Scot B. New techniques for evaluating lung immunology and immunopathology. Kradin RL, Robinson BWS eds. In: Immunopathology of lung disease. Butterworth Heinemannn, Troneham, MA 1996:541-567.
90. Robinson BWS. Sarciudisus, Kradin RL, Robinson BWS eds. In: Immunopathology of lung disease. Butterworth Heinemann, Stoneham, MA 1996:165-190.
91. Staton JM, Dench JE, Currie B, Fitzpatrick DR, Himbeck R, Allen R, Bruce J, Robinson BWS, Bielefeldt-Ohmann H. Expression and immune recognition of stress proteins in sarcoidosis and other chronic interstitial lung diseases. Immunol Cell Biol 1995;73:23-32.
92. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44.
93. Robinson BWS, Garlepp MJ, Scott B. Mesothelioma. In Crystal RG, West JB. Eds. The Lung: Scientific Foundations, Second Edition, 1995. Raven Press, New York 2599-2610.
94. Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS., Robinson BWS. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leukocytes and cytokine production in a murine model. Cancer Immunol, Immuno 1994;39:347-359.
95. Upham JW, Strickland DH, Bilyk N, Robinson BWS, Holt PG. Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion. Immunol 1995;84:142-147.
96. Garlepp MJ, Davidson JA, Leong CC, Robinson BWS. Gene therapy of malignant mesothelioma. In: The internet book of gene therapy: cancer therapeutics. Eds Sobol RE, Scanlon KJ, Appleton & Lange, Norwalk, CT, pp 257-268, 1995.
97. Bielefeldt-Ohmann H., Fitzpatric DR., Marzo AL., Jarnicki AG., Musk AW., Robinson BWS. Potential for Interferon-a -based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995;15:213-223.
98. Bielefeldt-Ohmann H., Marzo AL., Himbeck RP., Jarnicki AG., Robinson BWS., Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol, Immuno 1995;40:241-250.
99. Fitzpatrick DR, Manning LS, Musk AW, Robinson BWS, Bielefeldt-Ohmann H. Potential for cytokine therapy of malignant mesothelioma. Cancer Treatment Rev 1995;21:273-288.
100. Upham JW., Holt BJ., Baron-Hay MJ., Yabuhara A., Hales BJ., Thomas WR., Loh RKS., O'Keefe P., Palmer L., LeSouef P., Sly PD., Burton PR., Robinson BWS., Holt PG. Inhalant allergen-specific T cell reactivity is detectable in close to 100% of atopic and normal individuals: covert responses are unmasked by serum-free medium. Clin Exp Allergy 1995;24:634-642.
101. Davidson JA, Robinson BWS. Mesothelioma. Stuart-Harris R, Penny R eds. In, The Clinical Applications of the Interferons, 1995:225-235.
102. Jarnicki AG, Fitzpatrick DR, Robinson BWS, Bielefeldt-Ohmann H. Altered CD3 chain and cytokine gene expression in tumour infiltrating T lymphocytes (TIL) during the development of mesothelioma. Cancer Lett 1996;103:1-9.
103. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. Induction and maintenance of T cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene Therapy 1996;3:321-330.
104. Venaille TJ., Ryan G., Robinson BWS. Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum. Resp Med 1998:92;233-240.
105. Robinson BWS, Venaille TJ, Musk AW. Effects of a selection of asthma-inducing occupational agents on human epithelial cells. In Research Report 1994-95. National Occupational Health & Safety Commission, Australian Govt. Printing Office, Canberra. 129-131.
106. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol and Cell Biol 1997:75;356-359.
107. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. International J Cancer 1996;71:476-482.
108. Davidson JA, Musk AW, Wood Baker R, Morey S, Ilton M, Yu LL, Drury P, Shilkin K, Robinson BWS. Intralesional cytokine therapy in cancer; A pilot study of GM-CSF infusion in mesothelioma. J Immunotherapy 1998;21:389-398.
109. Marzo AL, Fitzpatrick DR, Robinson BWS, Scott B. Antisense oligonucleotides specific for transforming growth factor b2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Research 1997;57:3200-3207.
110. Upham JW, Strickland DH, Robinson BWS, Holt PG. Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages. Thorax 1997;52:786-795.
111. Robinson BWS, Mukherjee S, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi I, Scott B. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunotherapy 1998;21(3):211-217.
112. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BWS. Interleukin-12 induces an effective anti-tumour response in malignant mesothelioma. Am J Resp Cell Mol Biol 1998;19(5):738-46.
113. Robinson C, Robinson BWS, Lake RA. Sera from patients with malignant mesothelioma contain autoantibodies. Lung Cancer. 1998;20(3):175-84.
114. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BWS. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Onc 1999;17:25-30.
115. Lake RA, Robinson BWS, Hayball JD. MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. Immunol Cell Biology. 1999 77:99-104.
116. Marzo AL, Lake RA, Robinson BWS, Scott B T-Cell Receptor Transgenic Analysis of Tumor-specific CD8 and CD4 responses in the eradication of solid tumours. Cancer Res. 1999;59:1071-1079.
117. Pass HI, Robinson BWS, Testa JR, Carbone M. Emerging translational therapies for mesothelioma. Chest 1999;116:455S-460S
118. Marzo AL, Lake RA, Callow M, Robinson BWS, Scott BM, Lo D, Sherman L. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999; 162:5838-5845.
119. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BWS, Scott B. Cytokine gene therapy of mesothelioma: Immune and anti-tumor effects of transfected IL12. Am J Resp Cell Mol Biol. 1999, 21(3):347-356.
120. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson BWS. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Therapy. 2000,7(5):663-670.
121. Scott B, Mukherjee S, Lake R, Robinson BWS. Malignant Mesothelioma. In: Textbook of Lung Cancer. Ed Hanson H. London: Martin Dunitz; 2000.p.273-293.
122. McLaren B, Robinson BWS. Pathogenesis of Mesothelioma. In: Textbook of Respiratory Cell and Molecular Biology. Eds Hamid Q, Wardlaw AJ, Harwood Academic Publishers 1999. In Press.
123. Robinson BWS, Lake RA, Nelson DJ, Scott BA, Marzo AL. Cross-presentation of Tumour Antigens – Evaluation of Threshold, Duration, Distribution and Regulation. Immunol. Cell Biol. 1999:77:552-558.
124. Robinson C, Callow M, Stevenson S, Scott B, Robinson BWS, Lake RA. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J. Respir. Cell Mol. Biol. 2000;22:550-556.
125. McLaren BR, Robinson BWS, Lake RA. New chemotherapeutics in malignant mesothelioma: Effects on cell growth and IL6 production. Cancer Chemother Pharmacol. 2000;45(6):502-508.
126. Robinson BWS, Erle DJ, Jones DA, Shapiro S, Metzger WJ, Albelda S, Parks WC, Boylan A. Recent advances in molecular biological techniques and their relevance to pulmonary research. Thorax 2000;55:329-339.
127. Robinson BWS, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance. Clin Cancer Res. 2001;7(3 Suppl):811s-817s.
128. McLaren BR, Haenel T, Stevenson S, Mukherjee S, Robinson BWS, Lake RA. SV40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. .Aust NZ J Med. 2000;30(4):450-456.
129. Robinson BWS, Robinson C, Lake R. Localised spontaneous mesothelioma regression in mesothelioma – probable immunological mechanism. Lung Cancer. 2001;32(2):197-201.
130. Creaney J, McLaren BM, Musk AW, de Klerk N, Robinson BWS, Lake RA. P53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. BJ Cancer. 2001;84(1):52-56.
131. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BWS, Scott B. Tumor-Specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumour immunity. J Immunol. 2000;165(11):6047-6055.
132. Nelson DJ, Bundell C, Robinson BWS. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. J Immunol. 2000; 165:6123-6232.
133. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson BWS. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol. 2001;166:5557-5566.
134. Mukherjee S, Nelson DJ, Loh S, van Bruggen I, Palmer LJ, Leong C, Garlepp MJ, Robinson BWS. Gene therapy delays solid tumor growth if used in combination with debulking sugery. Cancer Gene Therapy. (Accepted 09.05.2001).
135. Robinson C, Callow M, Stevenson S, Robinson BWS, Lake RA. Private specificities can dominate the humoral response to self antigens in patients with cryptogenic fibrosing alveolitis. Respiratory Research. 2001;2:119-124.
(home)
136.     Nowak A, BWS Robinson & Richard A Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.  Cancer Research.  2002; 62(8) 2353-2358.
137.     Nowak A, Lake RA, Kindler HL, Robinson BWS.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.  Seminars in Oncology.  2002; 82-96
138.     McLaren B, Whitaker D, Robinson BWS, Lake RA.  Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma.  Cancer Chemother Pharmacol.  2001;48(1):1-8.
139.     Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BWS.  A multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma.  British Journal of Cancer.  2002; 87:491-496
140.     Nowak AK, Lake RA, Marzo AL, Scott B, Heath RW, Collins EJ, Frelinger JA, Robinson BWS.  Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T-cells.  J Immunol.  2003; 170:4905-4913.
141.     Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BWS, Nelson DJ.  Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine interleukin-12.  Cancer Gene Therapy.  2003;10:591-602.
142.     Nowak AK, Robinson BWS, Lake RA.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.  Cancer Research.  2003;63:4490-4496
143.     Jackaman C, Bundell C, Kinnear B, Smith A, Filion P, van Hagan D, Robinson BWS, Nelson D.  Interleukin-2 intra-tumoral immunotherapy enhances CD8+ cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol.  2003;171:5051-5063.
144.     Hayball JD, Robinson BWS, Lake RA.  CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells.  Imm Cell Biol.  In Press.  Accepted 15.11.03.
145.     Robinson BWS, Creaney J, Lake RA, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom E, Hellstrom I.  Mesothelin-family proteins and diagnosis of mesothelioma.  The Lancet 2003;362:1612-1616.
146.     Robinson BWS.  Soluble mesothelin-related protein – a sensitive new marker for mesothelioma.  Am J Oncol Rev. 2004;3:230-233
147.     Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, Robinson BWS.  Current treatment modalities in malignant mesothelioma.  Expert opinion in pharmacology. 
148.  Robinson BWS, Edwards MG. Climbing Mount Kilimanjaro in a Blizzard. Med J Aust. 2004;181 (11/12): 646-648
149. Stumbles PA, Himbeck R, Frelinger JJ, Lake RA, Robinson BWS.  Tumour-specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate Tumor Regression following Systemic CD40 Activation. J Immunol. 2004;173:5923-5928.
150.  Robinson BW, Musk AW, Lake RL.  Malignant Mesothelioma. The Lancet. In Press (accepted 12/04).
151. Lake RL, Robinson BW.  Immunotherapy as a preferred adjunct to chemotherapy. Nature Rev Cancer. In Press (accepted 01/05).
152.  Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.  Soluble mesothelin-related protein – A blood test for mesothelioma.  Lung Cancer. Article In Press.  March 2005.
153.   Creaney J, Robinson BW. Detection of mesothelioma in asbestos exposed individuals: The potential role of soluble mesothelin related protein.  Seminars in Haematology-Oncology. In press.
154.  Combining Immunotherapy With Chemotherapy to Treat Cancer. Robbert G. van der Most, Bruce W.S. Robinson and Richard
 A. Lake.
155. Nelson DJ, Robinson BW, Allan J, van der Most R.  Gene therapy of mesothelioma. Expert Opin Biol Ther. 2005
 Aug;5(8):1039-49.
156. van Bruggen I, Nelson DJ, Currie AJ, Jackaman C, Robinson BW.  Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother. 2005 Jul-Aug;28(4):359-67.
157. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BWS , Lake RA. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 2005 Sep 1;65:7580-4
158. Robinson BWS, Lake RL. Advances in Malignant Mesothelioma. New Eng J Med 2005;353:1591-603
159. Bundell CS, Jackaman C, Suhrbier A, Robinson BWS, Nelson DJ. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. (Epubmed ahead of print) Cancer Immunol Immunother. 2005 Nov 11; 1-15
160. van der Most RG, Currie A, Robinson BWS, Lake RA, Cranking the immunologic engine with chemotherapy: Using context to drive tumour antigen cross-presentation towards useful anti tumour immunity.  American Association for Cancer research 2006 Jan 15 66(2):601-4
161 van der Most RG, Robinson BWS, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years (Epubmed ahead of printing) Cancer Gene
162. Zhong J, Gencay-Cornelson MM, Bubendorf L, Burgess JK, Parson H, Robinson BWS, Tamm M, Black JL, Roth M. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP and TIMP and affect cell migration: a comparison between mesothelioma and mesothelial cells. Journal of  Cellular Physiology 2006 May; 207(2):540-52
163. Powell A, Creaney J, Broomfield S, van Bruggen I, Robinson BWS,  Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer, 2006 Mar 22; [Epubmed ahead of print] IN PRESS
164. Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clinical Cancer Res. 2006 Sep 1; 12 (17):5129-35  [IF: 5.175]
165  Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 2006 Oct 1;58(8):975-90. Epub 2006 Aug 15.  [IF: 7.189]
166. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, Robinson BW, Lake RA. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006 Nov 15;66(22):10786-94 [IF: 7.189]
167. Creaney J, Christansen H, Lake RA, Musk A.W, de Klerk N, Robinson BWS. Soluble mesothelin related protein in mesothelioma. 2006 Journal of Thoracic Oncology. 2;172-174 [IF: 7.616]
168. Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand M-C, Kjaerheim K, Pass HI, Robinson BWS, Tsao A. Outcomes from the Eighth International Mesothelioma Conference. Oncogene. In Press Accepted 13.02.07. [IF: 6.9]
169. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BWS. Soluble mesothelin in effusions – a useful tool for the diagnosis of malignant mesothelioma. Thorax (Accepted 04/01/2007) [IF: 6.150]